Welcome to our dedicated page for Selecta Biosciences news (Ticker: SELB), a resource for investors and traders seeking the latest updates and insights on Selecta Biosciences stock.
Selecta Biosciences, Inc. (symbol: SELB) is a clinical-stage biopharmaceutical company dedicated to enhancing the efficacy of biologic therapies by reducing unwanted immune responses. The company's innovative approach leverages its proprietary tolerogenic Synthetic Vaccine Particles (SVP™) technology, which is designed to enable a wide range of biologics, particularly for rare and serious diseases that lack effective treatment options.
Selecta's current pipeline features SVP-enabled enzyme, oncology, and gene therapies. Leading the pipeline is SEL-212, a promising candidate in Phase 2 trials targeting severe gout. SEL-212 aims to alleviate debilitating symptoms such as flares and gouty arthritis, offering much-needed relief to patients. Another noteworthy candidate is SEL-403, a combination therapy comprising SVP-Rapamycin and LMB-100, which entered Phase 1 trials in 2018 for treating malignant pleural or peritoneal mesothelioma.
In addition to enzyme and oncology therapies, Selecta is developing gene therapy product candidates designed for rare metabolic disorders. These candidates hold the potential to enable repeat dosing and long-term efficacy. The company’s research endeavors are backed by a series of collaborations and partnerships that bolster its scientific and commercial capabilities.
The company's latest news highlights significant progress in its clinical trials and partnerships. Notable developments include updates on the potential of its Descartes-08 and Descartes-15 therapies to treat myasthenia gravis and other autoimmune diseases, as well as advancements in RNA Armory® technology.
Selecta continues to focus on mitigating risks inherent in clinical trials, regulatory processes, and funding requirements. The company's strategic initiatives and forward-looking statements are guided by its commitment to addressing unmet medical needs and bringing innovative therapies to market.
Selecta Biosciences recently announced promising preclinical data supporting its ImmTOR platform's ability to enhance gene therapy. The study showed that co-administration of AAV8 and ImmTOR increased transgene expression and durability while mitigating neutralizing antibody formation, compared to AAV8 alone. The findings could allow for reduced doses and enable re-dosing of gene therapies. Selecta plans to further explore these benefits in clinical trials for MMA-101, targeting methylmalonic acidemia, in collaboration with AskBio, expected to begin in H1 2021.
On January 4, 2021, Selecta Biosciences (NASDAQ: SELB) announced participation in the H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. CEO Carsten Brunn, Ph.D., and CFO Brad Dahms will present at the event, which will be available on-demand starting January 11 at 6 a.m. EST. Selecta is known for its ImmTOR™ platform aimed at developing therapies that reduce unwanted immune responses. Their first clinical trial is set for early 2021, targeting methylmalonic acidemia in partnership with AskBio.
Selecta Biosciences (NASDAQ: SELB) and AskBio announced that their gene therapy MMA-101 for isolated methylmalonic acidemia (MMA) has received orphan drug and rare pediatric disease designations from the FDA. These designations are crucial for addressing the significant medical need for MMA treatments. The companies plan to initiate a Phase 1 clinical trial in the first half of 2021. Receiving these designations provides various benefits, including tax credits and the potential for market exclusivity following approval.
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company, announced CEO Carsten Brunn's participation in two upcoming virtual investor conferences in November 2020. The conferences include the Jefferies Virtual London Healthcare Conference on November 17, at 9:05 a.m. ET, and the Stifel 2020 Virtual Healthcare Conference on November 18, at 2 p.m. ET. Live webcasts will be accessible via Selecta’s website. The company focuses on developing therapies to manage immune responses using its ImmTOR™ platform, with clinical trials expected to start in early 2021.
Selecta Biosciences (NASDAQ: SELB) reported its Q3 2020 results, highlighting a cash position of $147.6 million, sufficient to fund operations into Q1 2023. Revenue for the quarter reached $4.6 million, mainly attributed to a license agreement with Sobi. The Phase 3 DISSOLVE program for SEL-212 has commenced, with topline data expected in H2 2022. Research and development expenses increased to $14.0 million due to new clinical trials. Selecta incurred a net loss of $9.7 million, an improvement from $12.0 million in Q3 2019.
Selecta Biosciences, Inc. (NASDAQ: SELB) is set to hold a conference call on November 5, 2020, at 8:30 a.m. ET to discuss its third-quarter financial results and operational highlights. The call will be accessible via phone and an archived webcast will be available on the company’s website. Selecta is focused on its ImmTOR™ platform for developing therapies to mitigate immune responses, with significant programs in the pipeline, including a clinical trial for treating a rare metabolic disorder in early 2021. More details can be found at their website.
Selecta Biosciences, Inc. (NASDAQ: SELB) and Asklepios BioPharmaceutical, Inc. announced that the FDA has granted Rare Pediatric Disease Designation to MMA-101 for treating isolated methylmalonic acidemia (MMA) linked to MMUT gene mutations. This designation highlights the unmet medical need for treatments affecting fewer than 200,000 children in the U.S. The companies plan to begin a Phase 1 clinical trial in the first half of 2021, focusing on new gene therapy approaches.
Selecta Biosciences (NASDAQ: SELB) has partnered with IGAN Biosciences to explore the application of ImmTOR™ technology in treating IgA Nephropathy (IgAN), a serious kidney condition with no approved therapies. The agreement includes preclinical research to assess the combination of ImmTOR and IGAN’s IgA protease, which has shown potential to mitigate kidney damage in previous studies. An Investigational New Drug application is anticipated in Q4 2021. Selecta aims to leverage its ImmTOR platform, previously validated in chronic refractory gout treatments, to advance IgAN solutions.
Selecta Biosciences (NASDAQ: SELB), a clinical-stage biotechnology firm, announced its CEO, Carsten Brunn, Ph.D., will participate in two upcoming investor conferences. The first is the Jefferies Virtual Gene Therapy/Editing Summit on October 1, 2020, at 4:30 p.m. ET. The second is the Chardan Virtual 4th Annual Genetic Medicines Conference on October 5, 2020, at 2:30 p.m. ET. Both events will be accessible via live webcasts on the company’s website. Selecta aims to develop immune tolerance therapies using its ImmTOR™ platform, with clinical trials expected to begin in early 2021.
On September 23, 2020, Selecta Biosciences (NASDAQ: SELB) announced the initiation of the Phase 3 clinical program for SEL-212, aimed at treating chronic refractory gout. The first patient has been randomized in the DISSOLVE program, which includes two double-blind, placebo-controlled studies. SEL-212 combines pegadricase with ImmTOR to maintain control over serum uric acid levels. Sobi is funding the program and will receive data in late 2022, with a Biologics License Application anticipated in Q1 2023. A milestone payment of $5 million will be made to Selecta by Sobi.
FAQ
What is the market cap of Selecta Biosciences (SELB)?
What does Selecta Biosciences, Inc. specialize in?
What is SEL-212?
What is the significance of SVP™ technology?
What are the current projects in Selecta's pipeline?
What recent achievements has Selecta Biosciences made?
What partnerships does Selecta Biosciences have?
What is SEL-403?
How does Selecta Biosciences address risks in clinical trials?
What are the potential applications of Selecta's gene therapy candidates?
What are the key developments in Selecta's latest news?
